Molecular Markers of Response to Chemoradiation in Localized Esophageal Cancer

局限性食管癌放化疗反应的分子标志物

基本信息

  • 批准号:
    7674679
  • 负责人:
  • 金额:
    $ 13.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-08-15 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this proposal is to determine if molecular markers found in pretreatment biopsy specimens can predict pathologic complete response (pathCR) in patients with esophageal cancer (EC) undergoing preoperative chemoradiation (CTRT). PathCR is defined as no residual carcinoma in a resected specimen. Patients with EC have a 5-year survival rate of <20%. Localized carcinoma (stage II or III) is frequently treated with preoperative CTRT, but this empirical approach results in heterogeneous and often unpredictable outcomes. Approximately 25% of patients achieve a pathCR and tend to survive longer than do the 75% who achieve <pathCR (i.e., have residual cancer). Current clinical parameters do not reliably predict outcome from therapy and modifying the type CTRT has little impact on the proportion of patients with a pathCR. Moreover, preoperative CTRT and surgery have dire toxicity and life altering consequences. This lack of ability to individualize therapy is a major obstacle in improving patient outcomes. A rational approach to individualized therapy is likely to occur through understanding the molecular biology of this cancer. To that aim, we conducted a preliminary study in EC patients. In a 19-patient pilot profiling study using Affymetrix U133A GeneChip. microarray, unsupervised hierarchical cluster analysis segregated patient's cancers into two subgroups (5 of 6 pathCR clustered in subtype I and 1 of 6 in subtype II). These data suggest that pathCR might segregate from <pathCR based on molecular markers but our data needs confirmation in a larger patient sample. In an expanded cohort, we may also find an improved model for predicting pathCR which would itself require validation. We propose to assess the gene expression profile of 120 patients to assess if a high (e80%) positive predictive value for pathCR can be achieved. The Specific Aims of the proposal are 1. Determine the gene expression profile of the new cohort of 120 patients with esophageal cancer treated with preoperative chemoradiation. 2: Construct statistical models that have a high positive predictive value for pathCR by the gene expression profile of 120 patients. The modeling will include: (a) Identification of subtypes of esophageal cancer by gene expression profiles that are highly homogeneous; (b) Build pathCR prediction models based on specific to subtypes of esophageal cancer as defined in 2(a) and also in the homogeneously treated subgroups. Our attempts to individualize patient's therapy based on molecular biology can pave the way to allow administration of effective therapy, improve safety, and preserve the esophagus in some patients. PUBLIC HEALTH RELEVANCE: This proposal is an early attempt to individualize therapy based on molecular biology for patients with esophageal cancer. Our goal is to pave the way for a strategy in the future that will allow administration of effective therapy, improve safety, and preserve the esophagus in some patients.
描述(由申请人提供):该提案的总体目标是确定在接受术前化学化学(CTRT)的食管癌(EC)患者中,预处理活检标本中发现的分子标记是否可以预测病理完全反应(PATHCR)。路径Cr被定义为切除的样品中无残留癌。 EC患者的存活率为5年<20%。局部癌(II期或III期)经常用术前CTRT治疗,但是这种经验方法会导致异质性且通常无法预测的结果。大约25%的患者达到了路径,并且往往比达到<PathCR的75%(即患有残留癌)的生存时间更长。当前的临床参数不能可靠地可靠地预测治疗的结果,并且修改CTRT对PATHCR患者的比例几乎没有影响。此外,术前CTRT和手术具有可怕的毒性和改变生活的后果。缺乏个性化治疗的能力是改善患者预后的主要障碍。通过了解该癌症的分子生物学,可能会发生一种合理的个性化治疗方法。为此,我们对EC患者进行了初步研究。在使用Affymetrix U133A Genechip的19名患者试点分析研究中。微阵列,无监督的层次群集分析将患者的癌症隔离为两个亚组(在亚型I中以6个路径群集中的5个中的5个,亚型II中的6个中的1个)。这些数据表明,PATHCR可能会根据分子标记与<路径分离,但我们的数据需要在较大的患者样本中确认。在扩展的队列中,我们还可以找到一个改进的模型来预测PathCR,这本身需要验证。我们建议评估120名患者的基因表达谱,以评估是否可以实现高(E80%)阳性预测值。该提案的具体目的是1。确定用术前化学放疗治疗的120例食管癌患者的新队列的基因表达谱。 2:构建统计模型,该模型具有120名患者的基因表达谱,对路径的阳性预测值很高。该建模将包括:(a)通过高度均匀的基因表达谱鉴定食管癌的亚型; (b)在2(a)和同质处理的亚组中定义的基于针对食管癌亚型的特定亚型的路径预测模型。我们试图基于分子生物学来个性化患者疗法的尝试可以为允许进行有效治疗,提高安全性并保留某些患者食管的方式铺平道路。公共卫生相关性:该建议是基于食管癌患者的分子生物学个性化治疗的早期尝试。我们的目标是为未来的策略铺平道路,以便在某些患者中进行有效治疗,改善安全性并保护食道。

项目成果

期刊论文数量(35)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells.
  • DOI:
    10.1007/s00595-020-02018-2
  • 发表时间:
    2020-10
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Harada, Kazuto;Patnana, Madhavi;Wang, Xuemei;Iwatsuki, Masaaki;Murphy, Mariela A. Blum;Zhao, Meina;Das, Prajnan;Minsky, Bruce D.;Weston, Brian;Lee, Jeffrey H.;Bhutani, Manoop S.;Estrella, Jeannelyn S.;Shanbhag, Namita;Ikoma, Naruhiko;Badgwell, Brian D.;Ajani, Jaffer A.
  • 通讯作者:
    Ajani, Jaffer A.
Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma.
  • DOI:
    10.1002/jso.24912
  • 发表时间:
    2018-03
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Mizrak Kaya D;Nogueras-González GM;Harada K;Amlashi FG;Roy-Chowdhuri S;Estrella JS;Das P;Lee JH;Weston B;Bhutani MS;Matamoros A Jr;Thomas I;Lin Q;Badgwell BD;Ajani JA
  • 通讯作者:
    Ajani JA
Recent trend in gastric cancer treatment in the USA.
美国胃癌治疗的最新趋势。
Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma.
  • DOI:
    10.1136/gutjnl-2020-322707
  • 发表时间:
    2021-11
  • 期刊:
  • 影响因子:
    24.5
  • 作者:
    Hao, Dapeng;He, Siyuan;Harada, Kazuto;Pizzi, Melissa Pool;Lu, Yang;Guan, Pujun;Chen, Lu;Wang, Ruiping;Zhang, Shaojun;Sewastjanow-Silva, Matheus;Abdelhakeem, Ahmed;Shanbhag, Namita;Bhutani, Manoop;Han, Guangchun;Lee, Jeffrey H.;Zhao, Shuangtao;Weston, Brian;Murphy, Mariela Blum;Waters, Rebecca;Estrella, Jeannelyn Santiano;Roy-Chowdhuri, Sinchita;Gan, Qiong;Lee, Ju-Seog;Peng, Guang;Hanash, Samir M.;Calin, George Adrian;Song, Xingzhi;Zhang, Jianhua;Song, Shumei;Wang, Linghua;Ajani, Jaffer A.
  • 通讯作者:
    Ajani, Jaffer A.
Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance.
YAP1 的减弱有可能靶向癌症干细胞以克服耐药性。
  • DOI:
    10.18632/oncoscience.449
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Harada,Kazuto;Song,Shumei;Ajani,JafferA
  • 通讯作者:
    Ajani,JafferA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jaffer A. Ajani其他文献

Su1950 Comparison of Lymph Node Detection on PET and EUS in Patients With Esophageal Cancer
  • DOI:
    10.1016/s0016-5085(13)61913-7
  • 发表时间:
    2013-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Amanpal Singh;Abhik Bhattacharya;Harshad S. Ladha;Nathaniel H. Kwak;Somashekar G. Krishna;William A. Ross;Manoop S. Bhutani;Jaffer A. Ajani;Jeremy J. Erasmus;Wayne L. Hofstetter;Stephen G. Swisher;Jeffrey H. Lee
  • 通讯作者:
    Jeffrey H. Lee
Future perspective of precision medicine based on ascites cells for gastric adenocarcinoma with peritoneal carcinomatosis
基于腹水细胞的胃腺癌腹膜癌精准医疗的未来展望
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kazuto Harada;Masaaki Iwatsuki;Shiro Iwagami;Yoshifumi Baba;Yuji Miyamoto;Naoya Yoshida1;Jaffer A. Ajani;Hideo Baba
  • 通讯作者:
    Hideo Baba
Su1956 Accuracy of Endoscopic Ultrasound in Differentiation of Mucosal and Submucosal Esophageal Cancer At a Tertiary Cancer Care Center
  • DOI:
    10.1016/s0016-5085(13)61919-8
  • 发表时间:
    2013-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Amanpal Singh;Wayne L. Hofstetter;Abhik Bhattacharya;Harshad S. Ladha;Wei Qiao;William A. Ross;Manoop S. Bhutani;Somashekar G. Krishna;Jaffer A. Ajani;Dipen Maru;Jeffrey H. Lee
  • 通讯作者:
    Jeffrey H. Lee
Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma
  • DOI:
    10.1016/j.jtcvs.2005.08.037
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    S. Chris Malaisrie;Wayne L. Hofstetter;Arlene M. Correa;Jaffer A. Ajani;Ritsuko R. Komaki;Zhongxing Liao;Alexandria Phan;David C. Rice;Ara A. Vaporciyan;Garrett L. Walsh;Sandeep Lahoti;Jeffrey H. Lee;Robert Bresalier;Jack A. Roth;Stephen G. Swisher
  • 通讯作者:
    Stephen G. Swisher
食道・食道胃接合部腺癌におけるoligometastasis対するConsolidative Local Therapyの有用性
局部巩固治疗对食管/食管胃交界处腺癌寡转移的作用
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    岩槻政晃;原田和人;Jaffer A. Ajani;馬場秀夫
  • 通讯作者:
    馬場秀夫

Jaffer A. Ajani的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jaffer A. Ajani', 18)}}的其他基金

Common Stem Cell of Origin for Junctional and Gastric Adenocarcinoma
交界腺癌和胃腺癌的共同起源干细胞
  • 批准号:
    10705117
  • 财政年份:
    2022
  • 资助金额:
    $ 13.86万
  • 项目类别:
Common Stem Cell of Origin for Junctional and Gastric Adenocarcinoma
交界腺癌和胃腺癌的共同起源干细胞
  • 批准号:
    10506192
  • 财政年份:
    2022
  • 资助金额:
    $ 13.86万
  • 项目类别:
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
食管或胃食管交界处 Gli-1 腺 CA 中 Hedgehog 信号传导的抑制
  • 批准号:
    8583913
  • 财政年份:
    2013
  • 资助金额:
    $ 13.86万
  • 项目类别:
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
食管或胃食管交界处 Gli-1 腺 CA 中 Hedgehog 信号传导的抑制
  • 批准号:
    8728168
  • 财政年份:
    2013
  • 资助金额:
    $ 13.86万
  • 项目类别:
Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
通过食管基因表达谱预测病理完全缓解
  • 批准号:
    7783447
  • 财政年份:
    2010
  • 资助金额:
    $ 13.86万
  • 项目类别:
Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
通过食管基因表达谱预测病理完全缓解
  • 批准号:
    8007387
  • 财政年份:
    2010
  • 资助金额:
    $ 13.86万
  • 项目类别:
Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
通过食管基因表达谱预测病理完全缓解
  • 批准号:
    8434173
  • 财政年份:
    2010
  • 资助金额:
    $ 13.86万
  • 项目类别:
Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
通过食管基因表达谱预测病理完全缓解
  • 批准号:
    8609004
  • 财政年份:
    2010
  • 资助金额:
    $ 13.86万
  • 项目类别:
Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
通过食管基因表达谱预测病理完全缓解
  • 批准号:
    8211057
  • 财政年份:
    2010
  • 资助金额:
    $ 13.86万
  • 项目类别:
Molecular Biomarkers as Classifiers to Individualize Therapy of Esophagus Cancer
分子生物标志物作为食管癌个体化治疗的分类器
  • 批准号:
    7778882
  • 财政年份:
    2009
  • 资助金额:
    $ 13.86万
  • 项目类别:

相似国自然基金

新型活性酯靶向赖氨酸的活细胞化学标记方法及其生物学应用
  • 批准号:
    22307084
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
元素标记单颗粒等离子体质谱数字检测新方法及其生物分析应用
  • 批准号:
    22374111
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
基于2bRAD-M技术探索尸体微生物基因组分子标记的时相变化规律及法医学应用
  • 批准号:
    82371896
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
基于深度学习的重度抑郁症亚型识别和个体化生物标记解析研究
  • 批准号:
    62301549
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
膝关节软骨退变多模态磁共振成像与软骨及滑膜相关生物标记物表达关系的实验研究
  • 批准号:
    82360339
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

WASHINGTON UNIVERSITY HUMAN TUMOR ATLAS RESEARCH CENTER
华盛顿大学人类肿瘤阿特拉斯研究中心
  • 批准号:
    10819927
  • 财政年份:
    2023
  • 资助金额:
    $ 13.86万
  • 项目类别:
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomes
根据循环肿瘤 DNA 评估前列腺癌表型和基因型分类作为预测治疗结果的生物标志物
  • 批准号:
    10804464
  • 财政年份:
    2023
  • 资助金额:
    $ 13.86万
  • 项目类别:
Integrating imaging and biopsy-derived molecular markers for the pre-surgical detection of indolent and aggressive early stage lung adenocarcinoma
整合成像和活检衍生的分子标记物,用于惰性和侵袭性早期肺腺癌的术前检测
  • 批准号:
    10737330
  • 财政年份:
    2023
  • 资助金额:
    $ 13.86万
  • 项目类别:
Validation and Early Commercialization of the ENVISAGE Assay, a Prognostic Test for Barrett's Esophagus
ENVISAGE 检测(Barrett 食管的预后检测)的验证和早期商业化
  • 批准号:
    10761328
  • 财政年份:
    2023
  • 资助金额:
    $ 13.86万
  • 项目类别:
Stratification of Cancer Risk in Patients with Non-Dysplastic Barrett's Esophagus using TissueCypher: The SCRiBE study
使用 TissueCypher 对非发育性巴雷特食管患者的癌症风险进行分层:SCRiBE 研究
  • 批准号:
    10561001
  • 财政年份:
    2023
  • 资助金额:
    $ 13.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了